Multimeric Biotherapeutics, Inc.
June 22, 2026
Theater 2
Type: Company Presentation
Focus Area:
Oncology
Multimeric Biotherapeutics is developing the FortiVac vaccine technology to elicit powerful CD8+ T cell responses that are curative against tumor cells and microbial pathogens. The initial indication is a therapeutic vaccine for HPV-associated cancers.
Company HQ City:
La Jolla
Company HQ State:
California
Company HQ Country:
United States
Year Founded:
2008
Lead Product in Development:
FortiVac-HPV for the immunotherapy of HPV-associated cancers
CEO
Richard S. Kornbluth, MD, PhD
Development Phase of Lead Product
Pre-Clinical
Number of Unlicensed Products Looking for Licensing
2
When you expect your next catalyst update?
Dec. 2027
What is your next catalyst (value inflection) update?
IND-enabling studies
Primary Speaker
)
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}